Daabacaadda labaad ee 2016 Tilmaamaha NCCN ee Kansarka Unugyada Yaryar ee Kansarka (V2.2016) ayaa inta badan cusbooneysiiya qaybaha soo socda ee ku saleysan V2.2015:
Cusboonaysiinta heerka qiimaynta hordhaca ah ee kansarka sanbabada
-
SCL-2: Bukaanada qaar ayaa loo dooran karaa hamiga dhuuxa lafta. Shuruudaha xulashada waxaa ka mid ah: erythrocytes (RBC) oo leh lobes oo ku jira xuubka dhiigga ee durugsan, neutropenia, ama trombocytopenia, taas oo sifo u ah dhuuxa lafta burada.
Cusboonaysiinta Daawaynta Hore (SCL-5)
-
Heerka caddaynta shucaaca ka hortagga intracranial (PCI) ee bukaannada qaba SCLC ballaaran ayaa laga soo yareeyay 1 ilaa 2A.
-
Shucaaca xabadka waxaa loo isticmaali karaa daweyn ahaan bukaanada leh heerar kala duwan.
Mabaadi'da kemotherabi ee kansarka sambabada unugyada yaryar (SCL-C)
-
Bendamustine waxaa loo isticmaali karaa sidii ikhtiyaar daawaynta labaad, heerka caddaynta 2B.
-
Jooji daawaynta qiyaasta 5-maalmood ee temozolomide.
Mabaadi'da Daaweynta Shucaaca ee Kansarka Sambabada Unugyada Yaryar (SCL-D)
-
Shucaaca sambabada oo loogu talagalay burooyinka heerka ballaaran. Shayga 1 sifada waxaa loo bedelay: "Xiritaanka shucaaca sambabada waxaa laga yaabaa inay ka faa'iidaystaan bukaanada qaba SCLC bukaanada kuwaas oo la doortay muddo balaadhan oo ay ka jawaabaan daaweynta kemotherabi. Daraasaduhu waxay muujiyeen in bukaannada ay leeyihiin isku-duubnida kansarka sanbabada oo wanaagsan Dulqaadasho, waxay yarayn kartaa heerka soo noqnoqda ee sambabada calaamadaha, waxayna sii dheerayn kartaa badbaadada muddada dheer ee bukaannada qaarkood. Tijaabada kiliinikada ee la kala soocay ee CREST ee Jarmalka waxay muujineysaa in qiyaasta shucaaca xabadka ee dhexdhexaadka ah ay hagaajin karto bukaanada SCLC oo leh waji ballaaran oo wax ku ool u ah kiimoterabiga 2-sano ee guud ahaan badbaadada guud iyo 6-bilood PFS, in kasta oo barta dhamaadka koowaad ee daraasadda, 1-sano guud badbaadada, si weyn uma kordhin. "
-
Kahortagga shucaaca craniocerebral (PCI), gelitaanka 1 ayaa loo beddelay: "Bukaannada SCLC ee leh wejiyo xaddidan ama ballaaran oo si fiican uga jawaabaya daaweynta kemotherabi, PCI waxay yareyn kartaa heerka metastasis maskaxda waxayna hagaajin kartaa badbaadada guud. Si kastaba ha ahaatee, inkastoo hogaanka Daraasad caafimaad oo la kala soocay oo PCI ay muujisay in PCI ay yarayn karto heerka metastases maskaxda. Natiijooyinka hordhaca ah ee daraasadda Japan ayaa muujisay in bukaannada aan lahayn maskax-maskaxeed oo lagu xaqiijiyay MRI aysan lahayn faa'iido muhiim ah ka dib PCI. Bukaannada aan helin PCI, dabagal joogto ah waa in loo tixgeliyo baaritaanka sawirka Maskaxda. "
-
Kahortagga shucaaca craniocerebral (PCI), gelitaanka 2 ayaa loo beddelay: "Waxaa lagu talinayaa: qiyaasta PCI ee shucaaca maskaxda oo dhan waa in 25Gy loo qaybiyaa 10 irradiations, 30Gy oo loo qaybiyay 10-15 irradiations, ama 24Gy oo loo qaybiyay 8 irradiations. Koorsada daawaynta ee gaaban (Tusaale ahaan, 20Gy oo loo qaybiyay 5 muuqaal) ayaa laga yaabaa inay aad ugu haboonaato bukaanada qaba bukaano kala duwan. Daraasadda PCI99-01 waxay ogaatay in bukaannada qaata qiyaasta 36Gy ay leeyihiin dhimasho sare iyo neurotoxicity joogto ah marka loo eego bukaannada qaba 25Gy."
